RU2016131412A - Применение парикальцитола для лечения воспалительной анемии - Google Patents
Применение парикальцитола для лечения воспалительной анемии Download PDFInfo
- Publication number
- RU2016131412A RU2016131412A RU2016131412A RU2016131412A RU2016131412A RU 2016131412 A RU2016131412 A RU 2016131412A RU 2016131412 A RU2016131412 A RU 2016131412A RU 2016131412 A RU2016131412 A RU 2016131412A RU 2016131412 A RU2016131412 A RU 2016131412A
- Authority
- RU
- Russia
- Prior art keywords
- paricalcitol
- dose
- epoetin
- week
- administration
- Prior art date
Links
- 208000007502 anemia Diseases 0.000 title claims 4
- 230000002757 inflammatory effect Effects 0.000 title claims 4
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 claims 15
- 229960000987 paricalcitol Drugs 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 3
- 108010002601 epoetin beta Proteins 0.000 claims 3
- 229960004579 epoetin beta Drugs 0.000 claims 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 108010067416 epoetin delta Proteins 0.000 claims 2
- 229950002109 epoetin delta Drugs 0.000 claims 2
- 108010030868 epoetin zeta Proteins 0.000 claims 2
- 229950005185 epoetin zeta Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108010019673 Darbepoetin alfa Proteins 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960005029 darbepoetin alfa Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP201430177 | 2014-02-11 | ||
| ES201430177A ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
| PCT/EP2015/050817 WO2015121022A1 (en) | 2014-02-11 | 2015-01-16 | Use of paricalcitol in the treatment of inflammatory anaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016131412A true RU2016131412A (ru) | 2018-03-15 |
Family
ID=51205045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016131412A RU2016131412A (ru) | 2014-02-11 | 2015-01-16 | Применение парикальцитола для лечения воспалительной анемии |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11464791B2 (enExample) |
| EP (1) | EP3104872B1 (enExample) |
| JP (1) | JP2017512753A (enExample) |
| KR (1) | KR20160113664A (enExample) |
| CN (1) | CN106061498B (enExample) |
| AR (1) | AR099330A1 (enExample) |
| AU (1) | AU2015217956B2 (enExample) |
| CA (1) | CA2938057A1 (enExample) |
| DK (1) | DK3104872T3 (enExample) |
| ES (2) | ES2472040B1 (enExample) |
| IL (1) | IL247207B (enExample) |
| MX (1) | MX365096B (enExample) |
| PT (1) | PT3104872T (enExample) |
| RU (1) | RU2016131412A (enExample) |
| UY (1) | UY35989A (enExample) |
| WO (1) | WO2015121022A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102504090B1 (ko) * | 2020-08-05 | 2023-02-24 | 경상국립대학교병원 | 조영제-유발 신독성 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004062620A2 (en) * | 2003-01-13 | 2004-07-29 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
| CA2563874A1 (en) * | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
| CN101610782A (zh) * | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
| CN102772364B (zh) * | 2011-05-13 | 2015-12-02 | 重庆华邦制药有限公司 | 帕立骨化醇的脂肪乳及其制剂和制备方法 |
-
2014
- 2014-02-11 ES ES201430177A patent/ES2472040B1/es not_active Expired - Fee Related
-
2015
- 2015-01-16 CN CN201580007824.4A patent/CN106061498B/zh active Active
- 2015-01-16 US US15/117,896 patent/US11464791B2/en active Active
- 2015-01-16 CA CA2938057A patent/CA2938057A1/en not_active Abandoned
- 2015-01-16 RU RU2016131412A patent/RU2016131412A/ru unknown
- 2015-01-16 ES ES15702156T patent/ES2728158T3/es active Active
- 2015-01-16 DK DK15702156.9T patent/DK3104872T3/da active
- 2015-01-16 EP EP15702156.9A patent/EP3104872B1/en active Active
- 2015-01-16 PT PT15702156T patent/PT3104872T/pt unknown
- 2015-01-16 KR KR1020167023202A patent/KR20160113664A/ko not_active Ceased
- 2015-01-16 AU AU2015217956A patent/AU2015217956B2/en active Active
- 2015-01-16 JP JP2016552329A patent/JP2017512753A/ja active Pending
- 2015-01-16 WO PCT/EP2015/050817 patent/WO2015121022A1/en not_active Ceased
- 2015-01-16 MX MX2016010104A patent/MX365096B/es active IP Right Grant
- 2015-02-10 UY UY35989A patent/UY35989A/es not_active Application Discontinuation
- 2015-02-10 AR ARP150100380A patent/AR099330A1/es unknown
-
2016
- 2016-08-10 IL IL247207A patent/IL247207B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2472040R1 (es) | 2014-09-18 |
| IL247207B (en) | 2020-02-27 |
| US11464791B2 (en) | 2022-10-11 |
| AU2015217956B2 (en) | 2019-04-04 |
| ES2728158T3 (es) | 2019-10-22 |
| US20160367571A1 (en) | 2016-12-22 |
| ES2472040B1 (es) | 2015-07-01 |
| CN106061498A (zh) | 2016-10-26 |
| MX365096B (es) | 2019-05-22 |
| JP2017512753A (ja) | 2017-05-25 |
| CA2938057A1 (en) | 2015-08-20 |
| DK3104872T3 (da) | 2019-06-17 |
| UY35989A (es) | 2015-03-27 |
| ES2472040A2 (es) | 2014-06-27 |
| KR20160113664A (ko) | 2016-09-30 |
| CN106061498B (zh) | 2019-12-06 |
| AR099330A1 (es) | 2016-07-13 |
| IL247207A0 (en) | 2016-09-29 |
| PT3104872T (pt) | 2019-06-11 |
| MX2016010104A (es) | 2017-01-06 |
| WO2015121022A1 (en) | 2015-08-20 |
| EP3104872A1 (en) | 2016-12-21 |
| AU2015217956A1 (en) | 2016-08-25 |
| EP3104872B1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201720163D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B | |
| HUE059584T2 (hu) | Gyógyszerészeti készítmény vérszegénység kezelésére | |
| SI3615014T1 (sl) | Topična farmacevtska sestava, ki obsega vsaj amitriptilin, za zdravljenje periferne nevropatske bolečine | |
| BR112018072201A2 (pt) | composição compreendendo o componente à base de naftoquinona como ingrediente ativo, para prevenir ou melhorar a fadiga, cachexia, dor, declínio cognitivo e redução de células estaminais hematopoiéticas que são efeitos colaterais relacionados as drogas para tratamento anticancerígino | |
| RU2016131454A (ru) | Применения витамина d и его композиций для антибиоза | |
| BR112018006206A2 (pt) | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa | |
| WO2016112875A3 (zh) | 二联苯衍生物及其应用 | |
| EA202090666A1 (ru) | Применение содержащей бензоат композиции для лечения глициновой энцефалопатии | |
| SI4081502T1 (sl) | Ko-kristal ketoprofena in njegova priprava, farmacevtski sestavki, ki ga vsebujejo, in njegova uporaba | |
| EA201991265A1 (ru) | Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат | |
| PT3888647T (pt) | Composição farmacêutica que contém inibidor duplo de ezh1/2 para ser utilizado como fármaco de combinação | |
| BR112017024126B8 (pt) | Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos | |
| MD20180049A2 (ro) | Compoziţie farmaceutică | |
| DK3650024T3 (da) | Farmaceutisk sammensætning til nasal indgivelse omfattende rifampiciner til behandling af demens | |
| JP2017512753A5 (enExample) | ||
| IL261929B (en) | Stable pharmaceutical preparations for topical administration and their use | |
| WO2015166418A3 (es) | Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
| GB201907547D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B | |
| RU2017129085A (ru) | Новый состав N-карбамоилметил-4-фенил-2-пирролидона | |
| IL281553A (en) | A compound containing oxadiazole and a pharmaceutical preparation containing it | |
| MX2016010104A (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria. | |
| GB201814764D0 (en) | Pharmaceutical compositions for the treatment of proteinopathies | |
| GB201905536D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of metabolic disorders | |
| GB201807222D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammation disorders |